[Immunomediation or hyperviscosity in rapidly progressive sensorineural hearing loss. A therapeutic approach].
BACKGROUND
To evaluate the therapeutic response and the rheologic and immunological characteristics in subjects bearing of rapidly progressive sensorineural hearing loss (RPSHL).


METHODS
A comparative prospective study on three groups of damaged ears treated with piracetam (n=29), corticosteroids (n=32) and plabcebo (n=25). Hearing loss and recovery level, whole blood filterability (WBF) and a Western-blot (WB) to anticochlear antibodies were evaluated.


RESULTS
Recovery average was 20,8 +/- 55,9% in the first group, with progressive of deafness in the rest (p<0,01). WB did not show differences among groups. The higher WBF at the end of therapy was detected on group 1 (20,36 +/- 2,54 Vs 18,42 +/- 3,42 microl/seg on group 3; p<0,05). Moreover, it impaired only on those treated with piracetam, with statistically significative differences over the other two groups.


CONCLUSIONS
We detected alterations on WBF in patients with RPSHL that justify the use of rheoactive measures as a pathophysiological therapy.
García Callejo
F J
FJ
Servicio de Otorrinolaringología, Hospital Clínico Universitario de Valencia. jgarciacall@hotmail.com
Ramírez Sabio
J B
JB
Conill Tobías
N
N
Sebastian Gil
E
E
Orts Alborch
M H
MH
Marco Algarra
J
J
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D001809:Blood Viscosity; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D010889:Piracetam